Physician profile
Robert J Staggs
NPI 1346254570
$1,135.51
in general payments reported to CMS, 2019-2025
27 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $67.09 · 2024: $307 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $256.28 | 2021-2025 | |
| Novo Nordisk INC | $120.87 | 2024-2025 | Rybelsus, Ozempic |
| Amgen INC. | $88.82 | 2024-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $66.64 | 2025 | Rexulti |
| Lundbeck LLC | $57.74 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $51.58 | 2024-2025 | Nuzyra |
| Genzyme Corporation | $43.09 | 2021 | |
| Astellas Pharma US INC | $36.82 | 2024-2025 | Veozah |
| Neurocrine Biosciences, INC. | $36.74 | 2024 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $36.48 | 2025 | Keveyis |
| Pfizer INC. | $33.39 | 2025 | |
| Csl Behring | $30.55 | 2021 | |
| Vericel Corporation | $26.11 | 2021 | |
| Dexcom, INC. | $23.23 | 2025 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $23.16 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $21.80 | 2024 | Gemtesa |
| Davol INC. | $21.80 | 2022 | |
| Axsome Therapeutics, INC. | $20.62 | 2024 | Auvelity |
| Bioventus LLC | $19.45 | 2022 | |
| Lilly USA, LLC | $17.67 | 2025 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $17.19 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $16.10 | 2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $15.77 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $14.58 | 2024 | Airsupra |
| Horizon Therapeutics Plc | $13.90 | 2022 | |
| Baudax Bio INC. | $13.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Staggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.